Concord Drugs Ltd.
Fundamentals
- Market cap
- ₹109 cr
- P/E
- 192.97×
- ROE
- 0.99%
- Debt / equity
- 0.56
- 52-week range
- 29.00 — 92.52
The timeline — 2 notes on Concord Drugs Ltd.
May 2026
- 27 May 26 · 4:37 PM IST Brief Brief · Earnings · Micro cap
Concord Drugs reports FY26 revenue growth to ₹75.85 crore
Standalone revenue doubled in FY26, though the market already received these figures in a prior filing.
- 27 May 26 · 4:31 PM IST Brief Brief · Earnings · Micro cap
Concord Drugs doubles revenue to ₹75.85 cr, but auditor flags receivables
Standalone revenue jumped 105% in FY26, yet the auditor raised concerns over ₹4.14 crore in long-overdue trade receivables.